COMMUNIQUÉS West-GlobeNewswire

Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
27/03/2024
I henhold til vedtægternes pkt. 4.5 indkaldes hermed til ordinær generalforsamling i Orphazyme A/S til afholdelse den 18. april 2024 kl. 15:00 på selskabets adresse hos Visionhouse, Lyskær 8A, 2730 Herlev med følgende [...]
Tevogen Bio Announces Series A-1 Preferred Stock Investment
27/03/2024
WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell [...]
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
27/03/2024
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of capability [...]
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
27/03/2024
PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the [...]
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
27/03/2024
Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic- [...]
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
27/03/2024
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference
27/03/2024
Live webcast presentation on Thursday, April 4 th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company [...]
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
27/03/2024
CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
27/03/2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies [...]
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
27/03/2024
PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain [...]
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
27/03/2024
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
27/03/2024
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Årsregnskab 2023 – Et begivenhedsrigt år for selskabet
27/03/2024
2023 var et begivenhedsrigt år for selskabet, hvor den primære fokus i første halvår bestod i at overlevere driften af den tidligere aktivitet til Zevra samt at forlige den anlagte retssag i USA. I maj 2023 blev en ny [...]
SFWJ/MedCana Announces Significant Progress Across Its Operations, Eyes Global Expansion and Enhanced Profitability
27/03/2024
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- via IBN -- SFWJ, doing business as MedCana, a leading entity in the cannabis and agricultural technology sectors, today announces remarkable advancements across its [...]
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
27/03/2024
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223 therapy in prostate [...]
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
27/03/2024
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA ® and dovitinib [...]
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
27/03/2024
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical [...]
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
27/03/2024
ROSCREA, Ireland and FREIBURG, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high [...]
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
27/03/2024
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s [...]

Pages